Proposed New York Legislation
Could Increase Prescription Drug Costs
$5.6 Billion Over 10 Years

Prepared for

PCMA
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION

May 2016
Executive Summary

In New York, the State Senate and the State Assembly are considering legislation that if enacted into law would raise prescription drug costs in the state by billions of dollars over the next decade and reduce the quality of care for patients taking specialty medications for conditions such as multiple sclerosis, hepatitis C, and rheumatoid arthritis. These bills effectively exempt retail pharmacies from meeting the same safety and performance standards—contractual *terms and conditions*—that health plans require of mail-service and specialty pharmacies.

Visante analyzed the potential cost impact of S. 2530 and A. 6194 based on the legislation’s likely impact of reducing the ability of plans to negotiate effective pharmacy network contracts in New York. Visante projects significant costs associated with this legislation.

Major Findings:

- If enacted, the legislation could increase prescription drug costs and related medical costs in New York by more than $350 million in 2017. Over 10 years, the estimated cost could be $5.6 billion.

- The legislation would raise costs and undermine care in New York by exempting retail pharmacies from meeting standards related to credentialing, drug utilization evaluation activities, clinical prior authorization, quality-of-care reviews, and formulary compliance.

- By reducing the effectiveness of pharmacy network contracts, the legislation is not likely to result in a rush of drugstores offering new price concessions, but rather the undermining of the current price concessions offered by mail-service and specialty pharmacies, which are based on superior economies of scale and performance in areas such as formulary compliance.

The major findings above are based on Visante estimates and published evidence, including a 2013 analysis by the Centers for Medicare and Medicaid Services (CMS) that found that mail-service prescription costs are an average of 16% lower than the same prescriptions filled at retail pharmacies. The proposed legislation would take away the ability of mail-service pharmacies to continue to provide such savings. Likewise, specialty pharmacies have demonstrated average savings of 10-20% on drug costs and non-drug medical costs compared to retail pharmacies. The legislation would put these savings at risk.
Proposed New York Legislation Could Increase Prescription Drug Costs by $5.6 Billion

Discussion

Mail-service pharmacies and specialty pharmacies are widely utilized by pharmacy benefit managers, health insurance companies, and plan sponsors to help manage prescription drug costs and improve quality of care. Much of these savings are derived from competitive pricing (i.e., lower prices for greater volume) and economies of scale (i.e., greater efficiencies with greater volume).

The Federal Trade Commission (FTC) reinforced these basic concepts in a letter to a New York Senator in 2011, which essentially states that reducing the effectiveness of pharmacy network contracts would result in increased costs to consumers and plan sponsors. In the words of FTC:

“By restricting a health plan’s ability to offer favorable treatment to a low cost mail order pharmacy, the Bill undercuts pharmacies’ incentives to bid aggressively for a share of that health plan’s business. Reducing those incentives is likely to raise the prices that consumers pay for the prescription drugs that their health plans cover. Some cost increases may be passed on to plan beneficiaries in the form of higher out-of-pocket prices.”

Proposed Legislation Would Exempt Retail Pharmacies from Key Safety and Performance Standards and Reduce the Effectiveness of Pharmacy Network Contracts

Current New York law requires that if a retail pharmacy agrees to the same reimbursement rate and—importantly—the same contractual terms and conditions as a mail-service pharmacy or other non-retail pharmacy, an insurer shall permit any covered prescription to be filled at that retail pharmacy and cannot impose a differential co-payment on the insured consumer if they elect to do so. The proposed state legislation would delete the key terms and conditions requirement. This would effectively exempt retail pharmacies from meeting the same safety and performance standards that plans require of mail-service and specialty pharmacies. In turn, this would effectively expand the applicability of New York’s current law, which would undermine volume-based pharmacy price concessions and substantially raise costs for both consumers and health plan sponsors.

How Contractual Terms and Conditions Enhance Pharmacy Safety and Performance

Terms and conditions in a typical pharmacy provider agreement relate to credentialing, drug utilization evaluation activities, clinical prior authorization requirements, quality-of-care reviews, formulary compliance, grievance resolution procedures, and other processes. Standards for these areas can differ greatly when a traditional retail drugstore is compared to a highly-automated mail-service pharmacy or a highly-credentialed specialty pharmacy.

---

For example, specialty pharmacies must meet many requirements to effectively handle injectable biologic medications that require refrigeration and can cost many thousands of dollars per dose. These requirements include:

- Providing round-the-clock access to pharmacists, nurses and clinicians dedicated to and specially trained with respect to the disease state treated by the drug, the specialty drug, and the drug’s potential side effects;
- Adhering to rigorous storage, shipping and handling standards to meet product label shipping requirements, such as temperature control, and timely deliveries of the product in optimal condition;
- Performing disease-specific and drug-specific patient care management services that meet the unique needs of each patient and that incorporate multiple safeguards when dispensing and delivering the drug to ensure patient safety;
- Collecting data and tracking outcomes for specific patients as required;
- Managing compliance and persistency of drug regimens for patients; and
- Managing care within manufacturer Risk Evaluation and Mitigation Strategies (REMS) program requirements, including REMS reporting, Phase IV trials, the dispensing of FDA trial drugs under strict protocols, and related clinical and cognitive counseling.

If the proposed legislation to remove the terms and conditions requirement were to pass, many retail pharmacies ill-equipped to handle any of these requirements would likely try to dispense specialty medications, which would likely reduce quality-of-care and increase non-drug medical costs, as well as compromise patient safety, which REMS are designed to address. This likely outcome is consistent with a recent national survey of 500 physicians who prescribe specialty medications which found that just 5% believed that all drugstores “have the expertise and capability to provide the different types of specialty medications to patients.”

Likewise, high-volume mail-service pharmacies must meet a plan’s performance requirements in areas related to dispensing accuracy, generic dispensing, formulary compliance, patient counseling, and prescription adherence programs. Exempting retail pharmacies from meeting these plan requirements would also result in higher costs and reduced quality of care.

**Current Savings from Mail-Service and Specialty Pharmacies**

A cost analysis conducted by CMS in 2013 compared mail-service pharmacies to retail pharmacies in Medicare Part D. The agency found that costs at mail-service pharmacies were 16% less than retail pharmacies across all drugs examined.

Many studies have also shown improved patient adherence to prescription regimens with mail-service pharmacies, and that improved patient adherence delivers improved clinical outcomes.

---


Proposed New York Legislation Could Increase Prescription Drug Costs by $5.6 Billion

and reduces non-drug medical costs.4, 5, 6, 7, 8, 9, 10, 11, 12, 13

Specialty pharmacy savings could also be affected by the proposed amendment to New York’s insurance law. For example, the Pennsylvania Medicaid program’s use of specialty pharmacies helped save 21% on overall health expenditures for beneficiaries using specialty drugs, including 12% on specialty drug costs and 56% on inpatient hospital costs.14 Numerous other studies have demonstrated that specialty pharmacies save 10-50% on drug costs and non-drug medical costs.15,16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29

---

19 Dorholt, M., “Advancing Drug Trend Management in the Medical Benefit,” Managed Care, June 2014.
25 Specialty Pharmacy News, Volume 10, Number 6, June 2013.
Proposed New York Legislation Could Increase Prescription Drug Costs by $5.6 Billion

Impact of Proposed Legislation on Prescription Costs in New York

By eroding the effectiveness of pharmacy network contracts, the proposed state legislation is likely to substantially increase costs to consumers and plan sponsors. The effect of the legislation would not likely be a rush of retail pharmacies offering new price concessions to compete with mail-service and specialty pharmacies, but rather the undermining of price concessions offered by mail-service and specialty pharmacies based on superior economies of scale and performance in areas such as formulary compliance.

Methodology and Estimates

This economic analysis assumes that the proposed amendment to NY insurance law (i.e., deleting the requirement that the pharmacy has to agree to the same terms and conditions as mail-service or other non-retail pharmacies) would effectively eliminate the savings currently being generated by mail-service pharmacies and specialty pharmacies for the commercial fully insured and individual markets impacted by the legislation. The following important assumptions were also incorporated into the analysis:

- Visante estimates that mail-service pharmacies save the equivalent of 15% of drug costs in plans with average use of mail-service compared to plans with limited use of mail-service pharmacies.
- Visante estimates that specialty pharmacies save the equivalent of 15% of specialty drug costs in plans with average use of specialty pharmacies compared to plans with limited use of specialty pharmacy management.
- The proposed amendment will limit the savings from specialty pharmacies and mail-service pharmacies. It would affect commercial fully insured and individual insurance but not self-insured commercial insurance, Medicare, or Medicaid.

Applying these Assumptions to Create an Estimated Cost of the Legislation

1. Total U.S. outpatient prescription drug expenditures for 2017 are projected to be $364 billion,\(^{30}\) with $254 billion being traditional (non-specialty) prescription drugs and $110 billion being specialty medications.\(^{31}\) For the 10-year period 2017-26, total outpatient drug expenditures are estimated at $4.9 trillion, with $2.9 trillion in spending on traditional medications and $2 trillion in spending on specialty medications.

2. Specific to the commercial insurance market, total U.S. outpatient prescription drug expenditures for 2017 are projected to be $190 billion, with $127 billion spent on traditional (non-specialty) prescription drugs and $63 billion spent on specialty medications. For the 10 year period 2017-26, total outpatient drug expenditures are estimated at $2.44 trillion, with $1.35 trillion in spending on traditional medications and $1.09 trillion in spending on specialty medications.

3. The projected expenditures for specialty medications above capture only the 50% of specialty expenditures that flow through the pharmacy benefit (potentially available for

---


\(^{31}\) Visante estimate based on published data from IMS Health and PBM Drug Trend Reports.
retail pharmacies). The other 50% flow through the medical benefit (i.e., physician offices, clinics, hospitals).  

4. Nationally, approximately 15% of traditional non-specialty outpatient drug expenditures flow through mail-service pharmacies in the commercial/private insurance market. Use of mail-service pharmacies is higher in commercial plans than in Medicare or Medicaid plans.

5. New York accounts for approximately 5.3% of U.S. drug expenditures in the commercial market, and 55% of the commercial market is in the fully insured and individual insurance markets that would be impacted by the legislation.

6. Therefore, the subset of drug expenditures in New York in 2017 that could potentially be affected by this legislation is $556 million ($5.9 billion over 10 years) for traditional non-specialty mail-service and $1.8 billion for specialty pharmacy ($31 billion over 10 years). These sum to $2.38 billion in combined traditional and specialty expenditures potentially impacted by the New York legislation in 2017, and $37 billion over 10 years.

7. Potential “Lost Savings” from Mail-Service Pharmacy and Specialty Pharmacy
   a. Mail-Service: Estimated savings of 15% = $83 million in 2017 ($0.9 billion over 10 years).
   b. Specialty: Estimated savings of 15% drug spend ($274 million in 2017, $4.7 billion over 10 years)
   c. Therefore, total potential “annual cost” of the legislation (based on “lost savings”) could be up to $357 million in 2017 or $5.6 billion over 10 years.

---

32 EMD Serono Specialty Digest™, 7th edition
33 Visante estimates.
34 US Census 2015
35 Kaiser Family Foundation, Health Insurance Coverage of the Total Population
36 MEPS, Percent of private-sector enrollees that are enrolled in self-insured plans at establishments that offer health insurance by firm size and State: United States, 2014